Archives | Eurobio-Scientific

Eurobio Scientific Team

Archivos

2023

Catherine Courboillet to join the Board as an Independant Member

I

I

Availability of the 2023 half-yearly financial report

I

I

GenDx reduces organ matching time to 3 hours

I

I

H1 2023 Results: Solid performance of Core Business and acceleration of strategic deployment

I

I

Acceleration of strategic deployment in the first half of 2023

I

I

Reducción de capital por anulación de acciones propias

I

I

All resolutions approved at the 2023 Annual General Meeting – The Board of Directors appoints a new governance

I

I

Acquisition of D.I.D. in Italy

I

I

First IVDR CE marking of PCR tests

I

I

Publication of the 2022 annual financial report

I

I

2022 annual results : very strong performance and strengthening of the Core Business

I

I

Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific

I

I

Eurobio Scientific formalises the appointment of Anne-Sophie Herelle as Group CFO

I

I

2022 annual turnover of €152.5M

I

I

H2 2022 report on the liquidity contract

I

I

2022

Exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

I

I

Half-year financial report available

I

I

H1 2022 Results: continued growth of non-COVID activity

I

I

Eurobio Scientific finalizes the acquisition of GenDx, international HLA diagnostics specialist

I

I

Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist

I

I

First half turnover of €83.6 million maintained at a high level

I

I

Half-year report on liquidity contract

I

I

Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox

I

I

Eurobio Scientific’s annual shareholders’ meeting

I

I

Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV

I

I

Closing of the Strategic Partnership with NEXTSTAGE AM

I

I

Availability of the 2021 annual financial report

I

I

Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility

I

I

CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2

I

I

Maintaining high level results in 2021

I

I

New priority test for the detection of Omicron BA.x, BA.2 and Delta of SARS-CoV-2

I

I

Strategic partnership with NextStage AM

I

I

2021 TURNOVER : Exceptional level of €184.1million

I

I

Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France

I

I

Eurobio Scientific confirms its eligibility to the pea-pme system

I

I